As for the 9-price vaccine, there are domestically produced and imported vaccines. Domestically produced vaccines are cheaper, while imported vaccines are more expensive.
The nine-valent HPV vaccine is used to prevent cervical cancer and other precancerous lesions or atypical lesions caused by HPV. It can prevent 92.1% of cervical cancer. Vaccination is primary prevention, and screening is secondary prevention. Both are equally important at present. Therefore, cervical cancer screening measures should not be relaxed due to vaccination.
On April 28, 2018, the State Food and Drug Administration approved the launch of the nine-valent human papilloma virus vaccine for the prevention of cervical cancer. In July 2018, the nine-valent HPV vaccine was launched in Guangdong. On August 16, Shenzhen’s first dose of 9-valent HPV vaccine was officially administered at the Luohu Adult Vaccination Clinic. In September, Beijing launched nine-price cervical cancer vaccination appointments.
Supplement:
The nine-valent cervical cancer vaccine has good immunogenicity. After completing the 3-dose vaccination program, the seroconversion rate of relevant types of serum antibodies can reach almost 100%. One month after completing the vaccination program, the peak geometric mean antibody titer can reach 100 times the antibody level after natural infection. In the next 2 months, the value drops to 10 times and remains at a plateau.
The antibody level of the vaccine can be maintained for at least 4 years. In clinical trials of the efficacy of the nine-valent cervical cancer vaccine, the primary endpoints were persistent infection with relevant HPV types, genital warts associated with relevant HPV types, cervical intraepithelial neoplasia (CIN), external genital or vaginal epithelium Intraneoplasia (VIN or VaIN).
Clinical trials have shown that vaccination with the nine-valent cervical cancer vaccine can produce good protective effects, and can effectively reduce persistent HPV infections of corresponding types and precancerous lesions of the cervix, vagina, and external genitalia. The protective effect is can reach over 90. The nine-valent cervical cancer vaccine contains VLPs of HPV-6 and HPV-11 types and has a good preventive effect on genital warts.
Reference for the above content? Nine-valent HPV vaccine-Baidu Encyclopedia